Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 805.24M | 768.73M | 760.53M | 727.79M | 606.84M | 524.04M |
Gross Profit | 146.51M | 126.69M | 144.84M | 138.40M | 135.31M | 137.59M |
EBITDA | 118.11M | 125.80M | 119.31M | 127.13M | 98.20M | 79.43M |
Net Income | 34.09M | 31.15M | 38.31M | 48.95M | 36.62M | 21.84M |
Balance Sheet | ||||||
Total Assets | 992.67M | 974.00M | 968.71M | 935.04M | 961.71M | 972.46M |
Cash, Cash Equivalents and Short-Term Investments | 260.20M | 258.50M | 239.75M | 255.24M | 263.61M | 302.48M |
Total Debt | 171.06M | 176.04M | 180.76M | 143.12M | 188.48M | 250.05M |
Total Liabilities | 424.96M | 395.08M | 421.26M | 380.37M | 395.08M | 442.85M |
Stockholders Equity | 561.90M | 573.00M | 541.85M | 549.47M | 561.83M | 525.21M |
Cash Flow | ||||||
Free Cash Flow | 29.23M | 31.19M | 2.01M | 98.66M | 40.08M | -6.24M |
Operating Cash Flow | 102.49M | 83.34M | 91.56M | 118.47M | 91.44M | 74.61M |
Investing Cash Flow | -73.94M | -51.38M | -88.76M | -19.16M | -50.46M | -80.06M |
Financing Cash Flow | -42.56M | -13.30M | -19.12M | -117.85M | -76.87M | 215.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | HK$665.44M | 40.04 | 1.07% | 8.04% | -1.20% | -87.51% | |
66 Neutral | HK$1.64B | 5.08 | 24.13% | 4.37% | -3.85% | -19.28% | |
58 Neutral | HK$900.00M | 24.39 | 5.60% | ― | -0.83% | -18.97% | |
55 Neutral | HK$428.89M | 20.43 | 2.73% | 2.48% | -0.69% | ― | |
54 Neutral | HK$1.22B | 46.85 | 1.27% | ― | -4.30% | 13.83% | |
51 Neutral | $7.86B | -0.26 | -41.41% | 2.22% | 22.87% | -2.01% | |
48 Neutral | HK$934.19M | ― | -10.78% | ― | -0.95% | -128.35% |
Honliv Healthcare Management Group Co Ltd held its annual general meeting on June 13, 2025, where all proposed resolutions were passed with unanimous approval. Key resolutions included the re-election of directors, authorization of directors’ remuneration, reappointment of PricewaterhouseCoopers as auditors, and granting mandates for share repurchase and issuance. These decisions reflect strong shareholder support and are likely to enhance the company’s governance and operational flexibility.